TW200635906A - Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine - Google Patents
Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicineInfo
- Publication number
- TW200635906A TW200635906A TW094145703A TW94145703A TW200635906A TW 200635906 A TW200635906 A TW 200635906A TW 094145703 A TW094145703 A TW 094145703A TW 94145703 A TW94145703 A TW 94145703A TW 200635906 A TW200635906 A TW 200635906A
- Authority
- TW
- Taiwan
- Prior art keywords
- disorders
- tetrazolone
- medicine
- anxiety
- imidazolone derivatives
- Prior art date
Links
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- OUOJIFQQBPKAMU-UHFFFAOYSA-N tetrazol-5-one Chemical class O=C1N=NN=N1 OUOJIFQQBPKAMU-UHFFFAOYSA-N 0.000 title abstract 2
- FFSJPOPLSWBGQY-UHFFFAOYSA-N triazol-4-one Chemical class O=C1C=NN=N1 FFSJPOPLSWBGQY-UHFFFAOYSA-N 0.000 title abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 208000019022 Mood disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229940123563 Alpha 2c adrenoceptor antagonist Drugs 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010012335 Dependence Diseases 0.000 abstract 1
- 125000000815 N-oxide group Chemical group 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000022821 personality disease Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention concerns substituted triazolone, tetrazolone and imidazolone derivatives according to the general Formula (I), a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective α2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and/or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and/or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04106817 | 2004-12-21 | ||
| EP05104873 | 2005-06-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200635906A true TW200635906A (en) | 2006-10-16 |
Family
ID=36013649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW094145703A TW200635906A (en) | 2004-12-21 | 2005-12-21 | Substituted triazolone, tetrazolone and imidazolone derivatives for use as a medicine |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20100029620A1 (en) |
| EP (1) | EP1831185A1 (en) |
| JP (1) | JP2008524312A (en) |
| KR (1) | KR20070090941A (en) |
| AR (1) | AR052342A1 (en) |
| AU (1) | AU2005318188A1 (en) |
| BR (1) | BRPI0516380A (en) |
| CA (1) | CA2588028A1 (en) |
| EA (1) | EA011514B1 (en) |
| IL (1) | IL184048A0 (en) |
| MX (1) | MX2007007472A (en) |
| NO (1) | NO20073760L (en) |
| PA (1) | PA8657301A1 (en) |
| TW (1) | TW200635906A (en) |
| WO (1) | WO2006067139A1 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2079694B1 (en) | 2006-12-28 | 2017-03-01 | Rigel Pharmaceuticals, Inc. | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use |
| EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
| AU2011308403B2 (en) * | 2010-10-01 | 2014-08-21 | Taisho Pharmaceutical Co., Ltd. | 1,2,4-triazolone derivative |
| FR2976287B1 (en) | 2011-06-09 | 2013-07-05 | Pf Medicament | BENZOQUINOLIZIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS |
| KR101998442B1 (en) * | 2011-10-27 | 2019-07-09 | 다이쇼 세이야꾸 가부시끼가이샤 | Azole derivative |
| CN104334547B (en) | 2012-05-22 | 2017-06-06 | 奥蒂福尼疗法有限公司 | Triazoles as KV3 inhibitors |
| KR20160018543A (en) * | 2013-06-11 | 2016-02-17 | 에프. 호프만-라 로슈 아게 | Novel tetrazolone derivatives |
| EP3013342B1 (en) | 2013-06-27 | 2021-04-14 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| US20190297887A1 (en) | 2016-07-12 | 2019-10-03 | Bayer Cropscience Aktiengesellschaft | Bicyclic compounds as pesticides |
| CA3079819C (en) * | 2017-11-06 | 2023-03-14 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to a.beta.42 oligomer formation |
| JP2021183586A (en) * | 2020-05-22 | 2021-12-02 | 武田薬品工業株式会社 | Heterocyclic compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3355457A (en) * | 1965-05-21 | 1967-11-28 | American Cyanamid Co | Substituted 2-imidazolinones |
| DE2725148A1 (en) * | 1977-06-03 | 1978-12-14 | Hoechst Ag | 1-ARYL-4-ALKYL-1,2,4-TRIAZOL-5-ONE AND METHOD FOR THE PRODUCTION THEREOF |
| PT741737E (en) * | 1994-01-24 | 2000-04-28 | Janssen Pharmaceutica Nv | ANTI-SPUNGERS OF THE AZOLE TYPE SOLUBLE IN WATER |
| JPH0899975A (en) * | 1994-08-05 | 1996-04-16 | Nippon Bayeragrochem Kk | Five-membered heterocyclic ring substituted tetrazolinone derivative and herbicide |
| JPH09183770A (en) * | 1995-10-31 | 1997-07-15 | Nippon Bayeragrochem Kk | Derivative of 1-azine-tetrazolinon and herbicide |
| WO1998025912A1 (en) * | 1996-12-13 | 1998-06-18 | E.I. Du Pont De Nemours And Company | Herbicidal heterocyclic amides |
| AU7365698A (en) * | 1997-05-15 | 1998-12-08 | E.I. Du Pont De Nemours And Company | Herbicidal tetrazolinones |
| EP0957101A1 (en) * | 1998-05-14 | 1999-11-17 | Janssen Pharmaceutica N.V. | Water soluble azoles as broad-spectrum antifungals |
| JP3837242B2 (en) * | 1998-08-25 | 2006-10-25 | 北興化学工業株式会社 | Triazolinone derivatives and herbicides |
| WO2000010984A1 (en) * | 1998-08-19 | 2000-03-02 | Hokko Chemical Industry Co., Ltd. | Triazolinone derivatives and herbicide compositions |
-
2005
- 2005-12-19 AR ARP050105336A patent/AR052342A1/en not_active Application Discontinuation
- 2005-12-20 US US11/722,380 patent/US20100029620A1/en not_active Abandoned
- 2005-12-20 EA EA200701345A patent/EA011514B1/en not_active IP Right Cessation
- 2005-12-20 MX MX2007007472A patent/MX2007007472A/en unknown
- 2005-12-20 AU AU2005318188A patent/AU2005318188A1/en not_active Abandoned
- 2005-12-20 CA CA002588028A patent/CA2588028A1/en not_active Abandoned
- 2005-12-20 PA PA20058657301A patent/PA8657301A1/en unknown
- 2005-12-20 WO PCT/EP2005/056951 patent/WO2006067139A1/en not_active Ceased
- 2005-12-20 JP JP2007547485A patent/JP2008524312A/en active Pending
- 2005-12-20 BR BRPI0516380-3A patent/BRPI0516380A/en not_active IP Right Cessation
- 2005-12-20 KR KR1020077014061A patent/KR20070090941A/en not_active Withdrawn
- 2005-12-20 EP EP05823472A patent/EP1831185A1/en not_active Withdrawn
- 2005-12-21 TW TW094145703A patent/TW200635906A/en unknown
-
2007
- 2007-06-19 IL IL184048A patent/IL184048A0/en unknown
- 2007-07-19 NO NO20073760A patent/NO20073760L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR052342A1 (en) | 2007-03-14 |
| PA8657301A1 (en) | 2007-01-17 |
| AU2005318188A1 (en) | 2006-06-29 |
| EA011514B1 (en) | 2009-04-28 |
| CA2588028A1 (en) | 2006-06-29 |
| EP1831185A1 (en) | 2007-09-12 |
| MX2007007472A (en) | 2007-07-20 |
| BRPI0516380A (en) | 2008-09-02 |
| JP2008524312A (en) | 2008-07-10 |
| EA200701345A1 (en) | 2007-10-26 |
| KR20070090941A (en) | 2007-09-06 |
| WO2006067139A1 (en) | 2006-06-29 |
| IL184048A0 (en) | 2007-10-31 |
| NO20073760L (en) | 2007-07-19 |
| US20100029620A1 (en) | 2010-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL198072A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| WO2007135131A8 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| NO20073760L (en) | Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2C adrenoceptor antagonists | |
| TW200420550A (en) | Thiazole compounds for the treatment of neurodegenerative disorders | |
| UA83899C2 (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
| CA2501799A1 (en) | Pyrazole compounds for treatment of neurodegenerative disorders | |
| WO2007141200A8 (en) | Novel n-aryl and n-heteroaryl substituted pyridinone derivatives for use in mch-1 mediated diseases | |
| TW200531689A (en) | Therapeutic agents | |
| MX386258B (en) | 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases | |
| DK1303495T3 (en) | Substituted 5-alkylnylpyrimidines with neurotrophic activity | |
| TW200504034A (en) | Therapeutic agents | |
| TW200635903A (en) | Therapeutic agents | |
| MX2009005908A (en) | Novel substituted diaza spiro pyridinone derivatives for use in mch-1 mediated diseases. | |
| TW200745135A (en) | Therapeutic agents | |
| CA2498291A1 (en) | Diazabicyclic compounds useful in the treatment of cns and other disorders | |
| TW200633986A (en) | Therapeutic agents | |
| TW200509933A (en) | Therapeutic agents | |
| TW200635589A (en) | Therapeutic agents | |
| IL194740A0 (en) | Substituted pyrazinone derivatives for use as a medicine | |
| IL192240A0 (en) | Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists | |
| MX2007006754A (en) | Indenyl derivatives and use thereof for the treatment of neurological disorders. | |
| TW200602297A (en) | Sulfonamide compounds for the treatment of neurodegenerative disorders | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| TW200734324A (en) | Therapeutic agents | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders |